



Bal Pharma Limited

01.04.2021

To,
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

BSE Limited
Mumbai.

Dear Sir,

Sub : Compliance with Regulation 30 of SEBI(SAST) Regulations ,2011.

With reference to the above, We are submitting to the exchanges disclosures received from promoters and PAC's of the Company for the financial year ended 31.3.2021, in compliance with Regulation 30 of SEBI (SAST) Regulations ,2011.

Please take the same on record.

Thanking You.

For Bal Pharma Limited

Authorised Signatory

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. : 41570813 / 19 Fax : 41570820

PART-B

Name of the Target Company: Bal Pharma Limited

Name of the person and person acting in concert (PAC) with the person.	Whether the person belonging to promoter/promoter group	PAN # of the person and PAC
Micro Labs Limited	Promoter	
Anand Surana	Promoter	
Dilip Surana	Promoter	
Archana Surana	Promoter	
Monica Surana	Promoter	
Dilip Surana (HUF)	Promoter	
Shailesh Siroya	Promoter	
Subbarao Prasanna	Promoter	
Anita Siroya	Promoter	
Chandraprakash Dheerajmal Siroya	Promoter	
Anita Chandraprakash Siroya	Promoter	
Jivi Dheerajmal Siroya	Promoter	
Shrenik D Siroya	Promoter	

For Bal Pharma Limited



Authorised Signatory.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)

Bal Pharma Limited

2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed

a) BSE Limited, Mumbai.

b) National Stock Exchange of India Limited, Mumbai.

3. Particulars of the Shareholders:

a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC

NA

Or

b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.

SHAILESH SIROYA

4. Particulars of the shareholding of person(s) mentioned at (3) above.

Number of Shares	% w.r.t. total share / voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:		
a) Shares	19,95,459	13.46%
b) Voting Rights (otherwise than by shares)		12.81%
c) Warrants,		
d) Convertible Securities		
e) any other instrument that would entitle the holder to receive shares in the TC.		
TOTAL	19,95,459	13.46%
		12.81%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2021


SHAILESH SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations, 2011.

With reference to the above, I would like to confirm that I have not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.



Shailesh Siroya

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	ANITA SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share / voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	10,49,220	7.08%	6.73%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	10,49,220	7.08%	6.73%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2021


ANITA SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations, 2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.


Anita Siroya

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	Dr.SUBBA RAO PRASANNA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of:			
a) Shares	20,200	0.14%	0.12%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	20,200	0.14%	0.12%


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2021


SUBBA RAO PRASANNA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.


Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations, 2011.

With reference to the above, I would like to confirm that I have not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2020.

Please take this intimation on record.

Thanking You.



Subha Rao Prasanna

C.C to The Chairman, Audit Committee


FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	SHRENIK D SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	0	0%	0%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	0	0%	0%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Place: Bangalore

Date: 31.03.2021



SHRENIK D SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.


Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations, 2011.

With reference to the above, I would like to confirm that I have not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.



Shrenik D Siroya

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	JIVI DHEERAJMAL SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share / voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	46,080	0.31%	0.29%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	46,080	0.31%	0.29%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Jivi D. Siroya

Place: Bangalore

Date: 31.03.2021

JIVI DHEERAJMAL SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.


Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations, 2011.

With reference to the above, I would like to confirm that I have not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.



Jivi Dheerajmal Siroya

C.C to The Chairman, Audit Committee


FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	CHANDRAPRAKASH DHEERAJMAL SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	4,86,420	3.28%	3.12%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	4,86,420	3.28%	3.12%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.



Place: Bangalore

Date : 31.03.2021

CHANDRAPRAKASH DHEERAJMAL SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.


Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations, 2011.

With reference to the above, I would like to confirm that I have not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.



Chandraprakash Dheerajmal Siroya

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	ANITA CHANDRAPRAKASH SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share / voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	1,22,687	0.83%	0.79%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	1,22,687	0.83%	0.79%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Anita Chandraprakash Siroya

Place: Bangalore

Date: 31.03.2021

ANITA CHANDRAPRAKASH SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.


Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations, 2011.

With reference to the above, I would like to confirm that I have not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.



Anita Chandraprakash Siroya

C.C to The Chairman, Audit Committee

**FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI
(Substantial Acquisition of Shares & Takeovers) Regulations, 2011**

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA MICRO LABS LIMITED		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of: a)Shares b)Voting Rights (otherwise than by shares) c)Warrants, d)Convertible Securities e)any other instrument that would entitle the holder to receive shares in the TC.	13,10,836	8.84%	8.42%
TOTAL	13,10,836	8.84%	8.42%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2021

For MICRO LABS LIMITED


Gunjan Kumar Chaurasia
Company Secretary



To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, We would like to confirm that we has not made any encumbrance on our shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

For Micro Labs Limited



Company Secretary

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA DILIP SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	4,74,994	3.20%	3.05%
TOTAL	4,74,994	3.20%	3.05%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2021


DILIP SURANA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations, 2011.

With reference to the above, I would like to confirm that I have not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

A handwritten signature in black ink, appearing to be 'Dilip Surana', written in a cursive style.

Dilip Surana

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA DILIP SURANA (HUF)		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	1,69,995	1.15%	1.09%
TOTAL	1,69,995	1.15%	1.09%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2021


DILIP SURANA (HUF)

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

A handwritten signature in black ink, appearing to be 'Dilip Surana', written in a cursive style.

Dilip Surana (HUF)

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA ANAND SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares.	% w.r.t. total share /voting capital wherever applicable.	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	5,25,686	3.55%	3.37%
TOTAL	5,25,686	3.55%	3.37%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2021



ANAND SURANA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations, 2011.

With reference to the above, I would like to confirm that I have not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

A handwritten signature in black ink, appearing to read 'Anand Surana', with a stylized flourish at the end.

Anand Surana

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA ARCHANA SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share / voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	2,84,996	1.92%	1.83%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	2,84,996	1.92%	1.83%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2021



ARCHANA SURANA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations, 2011.

With reference to the above, I would like to confirm that I have not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.



Archana Surana

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011


1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA MONICA SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	1,79,909	1.21%	1.15%
TOTAL	1,79,909	1.21%	1.15%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2021


MONICA SURANA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.


Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.

A handwritten signature in black ink, appearing to read 'Monika Surana', with a stylized flourish at the end.

Monika Surana

C.C to The Chairman, Audit Committee